Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$68.73 USD
-0.91 (-1.31%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $68.64 -0.09 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
EXAS 68.73 -0.91(-1.31%)
Will EXAS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
EW Stock Dips Following the Divestiture of Critical Care Wing
Other News for EXAS
Exact Sciences Corp (EXAS) Trading 3.05% Higher on Sep 19
10 Health Care Stocks With Whale Alerts In Today's Session
28 Top rated U.S. growth stocks month-to-date in anticipation of Fed cuts
Buy Rating Affirmed for Exact Sciences Following Promising CRC Screening Test Data
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential